Previous 10 |
home / stock / ipsef / ipsef news
Exelixis (NASDAQ: EXEL ) announces that commercialization partner Ipsen ( OTCPK:IPSEY )( OTCPK:IPSEF ) has received a positive opinion from the European Commission's Committee for Medicinal Products for Human Use (CHMP) backing approval for CABOMETYX (cabozantinib) for the first-line treat...
The following slide deck was published by Ipsen S.A. ADR in conjunction with this Read more ...
Exelixis (NASDAQ: EXEL ) +2.5% after-hours after announcing with partner Ipsen ( OTCPK:IPSEF , OTCPK:IPSEY ) that its cabozantinib cancer drug achieved its primary endpoint in a late-stage study and will be submitted to the FDA before the end of the quarter. More news on: Exelixis, In...
News, Short Squeeze, Breakout and More Instantly...
Ipsen Sa Ord Company Name:
IPSEF Stock Symbol:
OTCMKTS Market:
Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potential FS001 targets a novel tumor associated antigen, highly expressed across a range of solid tumors, identified throug...
Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx ® (cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and Japan Agreemen...
Iqirvo ® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial data Primary biliary cholan...